Anti-Endomucin 抗体 [V.7C7.1] (ab106100)
Key features and details
- Rat monoclonal [V.7C7.1] to Endomucin
- Suitable for: IHC-Fr, IHC-P, IP, Flow Cyt, WB, IHC - Wholemount, ICC/IF
- Reacts with: Mouse
- Isotype: IgG2a
製品の概要
-
製品名
Anti-Endomucin antibody [V.7C7.1]
Endomucin 一次抗体 製品一覧 -
製品の詳細
Rat monoclonal [V.7C7.1] to Endomucin -
由来種
Rat -
アプリケーション
適用あり: IHC-Fr, IHC-P, IP, Flow Cyt, WB, IHC - Wholemount, ICC/IFmore details
適用なし: FuncS -
種交差性
交差種: Mouse
非交差種: Human -
免疫原
Other Immunogen Type corresponding to Mouse Endomucin. Mouse endomucin-IgG fusion protein
-
特記事項
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
製品の特性
-
製品の状態
Liquid -
保存方法
Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles. -
バッファー
Preservative: 0.02% Sodium azide
Constituents: 0.1% BSA, PBS -
Concentration information loading...
-
精製度
Protein G purified -
特記事項(精製)
0.2 µm filtered solution -
ポリ/モノ
モノクローナル -
クローン名
V.7C7.1 -
アイソタイプ
IgG2a -
研究分野
関連製品
-
Compatible Secondaries
-
Isotype control
-
Recombinant Protein
アプリケーション
The Abpromise guarantee
Abpromise保証は、 次のテスト済みアプリケーションにおけるab106100の使用に適用されます
アプリケーションノートには、推奨の開始希釈率がありますが、適切な希釈率につきましてはご検討ください。
アプリケーション | Abreviews | 特記事項 |
---|---|---|
IHC-Fr |
Use at an assay dependent concentration.
|
|
IHC-P | (4) |
Use at an assay dependent concentration.
|
IP |
Use at an assay dependent concentration.
|
|
Flow Cyt |
Use at an assay dependent concentration.
ab18450 - Rat monoclonal IgG2a, is suitable for use as an isotype control with this antibody. |
|
WB |
Use at an assay dependent concentration.
|
|
IHC - Wholemount | (1) |
Use at an assay dependent concentration.
|
ICC/IF |
Use a concentration of 1 µg/ml.
|
特記事項 |
---|
IHC-Fr
Use at an assay dependent concentration. |
IHC-P
Use at an assay dependent concentration. |
IP
Use at an assay dependent concentration. |
Flow Cyt
Use at an assay dependent concentration. ab18450 - Rat monoclonal IgG2a, is suitable for use as an isotype control with this antibody. |
WB
Use at an assay dependent concentration. |
IHC - Wholemount
Use at an assay dependent concentration. |
ICC/IF
Use a concentration of 1 µg/ml. |
ターゲット情報
-
機能
Endothelial sialomucin, also called endomucin or mucin-like sialoglycoprotein, which interferes with the assembly of focal adhesion complexes and inhibits interaction between cells and the extracellular matrix. -
組織特異性
Expressed in heart, kidney and lung. -
翻訳後修飾
Highly O-glycosylated. Sialic acid-rich glycoprotein. -
細胞内局在
Secreted and Cell membrane. Membrane. Consistently localized to the plasma membrane and less abundantly to Golgi-like perinuclear stacks. - Information by UniProt
-
参照データベース
- Entrez Gene: 59308 Mouse
- SwissProt: Q9R0H2 Mouse
- Unigene: 27343 Mouse
-
別名
- EMCN antibody
- EMCN2 antibody
- Endomucin 2 antibody
see all
画像
プロトコール
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
データシートおよび資料
-
SDS download
-
Datasheet download
参考文献 (57)
ab106100 は 57 報の論文で使用されています。
- Himmels P et al. T cell-dependent bispecific antibodies alter organ-specific endothelial cell-T cell interaction. EMBO Rep 24:e55532 (2023). PubMed: 36621885
- Tang AT et al. Cell-autonomous requirement for ACE2 across organs in lethal mouse SARS-CoV-2 infection. PLoS Biol 21:e3001989 (2023). PubMed: 36745682
- Wu X et al. Generation of Conditional Knockout Alleles for PRUNE-1. Cells 12:N/A (2023). PubMed: 36831191
- Zhou T et al. Spatiotemporal Characterization of Human Early Intervertebral Disc Formation at Single-Cell Resolution. Adv Sci (Weinh) 10:e2206296 (2023). PubMed: 36965031
- Panebianco C et al. Counteracting gemcitabine+nab-paclitaxel induced dysbiosis in KRAS wild type and KRASG12D mutated pancreatic cancer in vivo model. Cell Death Discov 9:116 (2023). PubMed: 37019893